Head-To-Head Analysis: Neovasc (NVCN) and Its Rivals
Neovasc (NASDAQ: NVCN) is one of 78 public companies in the “Advanced Medical Equipment & Technology” industry, but how does it compare to its peers? We will compare Neovasc to similar companies based on the strength of its earnings, analyst recommendations, profitability, valuation, dividends, risk and institutional ownership.
This is a summary of recent ratings and target prices for Neovasc and its peers, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Neovasc currently has a consensus price target of $6.33, suggesting a potential upside of 657.58%. As a group, “Advanced Medical Equipment & Technology” companies have a potential downside of 9.78%. Given Neovasc’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Neovasc is more favorable than its peers.
Institutional and Insider Ownership
19.3% of Neovasc shares are held by institutional investors. Comparatively, 50.2% of shares of all “Advanced Medical Equipment & Technology” companies are held by institutional investors. 18.4% of shares of all “Advanced Medical Equipment & Technology” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Volatility & Risk
Neovasc has a beta of 1.77, meaning that its share price is 77% more volatile than the S&P 500. Comparatively, Neovasc’s peers have a beta of 1.27, meaning that their average share price is 27% more volatile than the S&P 500.
This table compares Neovasc and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings and Valuation
This table compares Neovasc and its peers top-line revenue, earnings per share and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Neovasc||$9.51 million||-$86.49 million||3.10|
|Neovasc Competitors||$2.14 billion||$229.91 million||-30.74|
Neovasc’s peers have higher revenue and earnings than Neovasc. Neovasc is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Neovasc beats its peers on 7 of the 13 factors compared.
Neovasc Company Profile
Neovasc Inc. (Neovasc) is a specialty medical device company. The Company develops, manufactures and markets products for the cardiovascular marketplace. The Company’s segment is the development, manufacture and marketing of medical devices. Its products include the Tiara technology in development for the transcatheter treatment of mitral valve disease, the Neovasc Reducer for the treatment of refractory angina, and tissue products. The Tiara is in preclinical/early clinical stage development to provide a minimally invasive transcatheter device for patients experiencing mitral regurgitation (MR) as a result of mitral heart valve disease. The Reducer is an hourglass-shaped, balloon-expandable, stainless steel, bare metal device, which is implanted in the coronary sinus, creating a restriction in venous outflow from the myocardium (the muscular layer of the heart wall). Neovasc produces Peripatch, a biological tissue product that is manufactured from pericardium.
Receive News & Ratings for Neovasc Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neovasc Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.